Cargando…

Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway

Epigenomic abnormalities caused by genetic mutation in epigenetic regulators can result in neurodevelopmental disorders, deficiency in neural plasticity and mental retardation. As a histone demethylase, plant homeodomain finger protein 8 (Phf8) is a candidate gene for syndromal and non-specific form...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xuemei, Wang, Shuai, Zhou, Ying, Han, Yanfei, Li, Shengtian, Xu, Qing, Xu, Longyong, Zhu, Ziqi, Deng, Youming, Yu, Lu, Song, Lulu, Chen, Adele Pin, Song, Juan, Takahashi, Eiki, He, Guang, He, Lin, Li, Weidong, Chen, Charlie Degui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760733/
https://www.ncbi.nlm.nih.gov/pubmed/29317619
http://dx.doi.org/10.1038/s41467-017-02531-y
Descripción
Sumario:Epigenomic abnormalities caused by genetic mutation in epigenetic regulators can result in neurodevelopmental disorders, deficiency in neural plasticity and mental retardation. As a histone demethylase, plant homeodomain finger protein 8 (Phf8) is a candidate gene for syndromal and non-specific forms of X-chromosome-linked intellectual disability (XLID). Here we report that Phf8 knockout mice displayed impaired learning and memory, and impaired hippocampal long-term potentiation (LTP) without gross morphological defects. We also show that mTOR signaling pathway is hyperactive in hippocampus in Phf8 knockout mouse. Mechanistically, we show that demethylation of H4K20me1 by Phf8 results in transcriptional suppression of RSK1 and homeostasis of mTOR signaling. Pharmacological suppression of mTOR signaling with rapamycin in Phf8 knockout mice recovers the weakened LTP and cognitive deficits. Together, our results indicate that loss of Phf8 in animals causes deficient learning and memory by epigenetic disruption of mTOR signaling, and provides a potential therapeutic drug target to treat XLID.